ANDA 207094, held by Sciegen Pharms. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 207094 (Triamcinolone Acetonide), held by Sciegen Pharms, was first approved by FDA on Dec 7, 2016, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 7, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.147MG/GM ยท spray;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
